You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 136 No. 3, March 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (10)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Dermatology, Other
 •Alert me on articles by topic

Cutaneous Aspergillosis and Acquired Immunodeficiency Syndrome

George J. Murakawa, MD, PhD; Jeff D. Harvell, MD; Paul Lubitz, MD; Sanford Schnoll, MD; Sue Lee, MD; Timothy Berger, MD

Arch Dermatol. 2000;136:365-369.

Background  Primary cutaneous aspergillosis is an uncommon finding in patients with acquired immunodeficiency syndrome (AIDS); only 13 cases have been reported in the literature.

Observations  We describe 11 patients with primary cutaneous aspergillosis and AIDS. There does not seem to be an age, sex, race, or human immunodeficiency virus risk factor predisposition. This is a late manifestation of AIDS; patients typically have low CD4 counts (<0.050 x 109/L [<50/µL]) and other AIDS-defining illnesses. The most frequent presentation is in patients with cytomegalovirus disease and neutropenia caused by ganciclovir therapy. Lesions developed at the site of occlusive dressings for an indwelling intravenous catheter site in 10 patients. Neutrophil counts may be normal at the time of diagnosis. A minor presentation is in the patient without neutropenia as a result of traumatic inoculation. Histological findings and/or culture results are required for diagnosis. Patients develop cutaneous lesions despite prophylactic therapy with fluconazole. Lesions can be treated with excision and lifelong therapy with itraconazole.

Conclusion  Because of the potential morbidity and mortality of cutaneous aspergillosis, a high level of suspicion and prompt institution of therapy is required.


From the Departments of Dermatology, University of California, San Francisco (Drs Murakawa, Lubitz, Lee, and Berger) and Davies Medical Center (Dr Schnoll), San Francisco, Calif; the Division of Dermatology, Albany Medical College, Albany NY (Dr Murakawa); and Stanford University School of Medicine, Stanford, Calif (Dr Harvell).


RELATED ARTICLES

Human Immunodeficiency Virus Infection and Cutaneous Aspergillosis
Emmanuel Roilides and Evangelia Farmaki
Arch Dermatol. 2000;136(3):412-414.
EXTRACT | FULL TEXT  

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2000;136(3):438-439.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Primary Cutaneous Aspergillus Infection in Patients with AIDS
Journal Watch Dermatology 2000;2000:4-4.
FULL TEXT  

Human Immunodeficiency Virus Infection and Cutaneous Aspergillosis
Roilides and Farmaki
Arch Dermatol 2000;136:412-414.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.